<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Neonatal hypoxic-ischemic <z:hpo ids='HP_0001298'>encephalopathy</z:hpo> (HIE) is a major cause of neurological disability requiring newer therapeutic strategies </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="16704">Uridine</z:chebi> is the principal circulating <z:chebi fb="0" ids="16898">pyrimidine</z:chebi> in humans and a substrate for <z:chebi fb="9" ids="36976">nucleotides</z:chebi> and membrane <z:chebi fb="1" ids="16247">phospholipids</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>The objective of this study was to investigate the effects of <z:chebi fb="0" ids="16704">uridine</z:chebi> in a neonatal rat model of HIE </plain></SENT>
<SENT sid="3" pm="."><plain>Rat pups subjected to hypoxic-ischemic insult on postnatal day 7 were injected intraperitoneally with either saline or <z:chebi fb="0" ids="16704">uridine</z:chebi> (100, 300 or 500mg/kg) for three consecutive days and brains were collected for evaluation of brain <z:mpath ids='MPATH_124'>infarct</z:mpath> volume and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="4" pm="."><plain>Compared with control group, <z:chebi fb="0" ids="16704">uridine</z:chebi> at 300 and 500mg/kg doses significantly reduced percent <z:mpath ids='MPATH_124'>infarct</z:mpath> volume, TUNEL(+) cell ratio and active Caspase-3 immunoreactivity in the cortex, as well as in CA1 and CA3 regions of the hippocampus </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="16704">Uridine</z:chebi> (300 and 500mg/kg) also decreased active Caspase-3 expression in the ipsilateral hemisphere </plain></SENT>
<SENT sid="6" pm="."><plain>These data indicate that <z:chebi fb="0" ids="16704">uridine</z:chebi> dose-dependently reduces brain injury in a rat model of neonatal HIE by decreasing <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
</text></document>